Shandi Husen, APRN
Nurse Practitioner · Wichita, KSNPI 1518469428
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,586 of the $7,212 with a category attached, or 77.4%. It is spread thinly across 38 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,254, 2.1 times the $1,094 reported in 2021. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Dendreon Pharmaceuticals LLC$940
- Johnson & Johnson$612
- Astellas Pharma US Inc$569
- Janssen Scientific Affairs, LLC$563
- Merck$376
- plus $3K from 32 others
What the payments were for
- Consulting fees$1,28318%
- Food & beverage$5,58677%
- Education$3445%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 29 | $1,230 |
| Dendreon Pharmaceuticals LLC | 34 | $940 |
| Johnson & Johnson | 26 | $612 |
| Astellas Pharma US Inc | 35 | $569 |
| Janssen Scientific Affairs, LLC | 1 | $563 |
| Merck | 24 | $376 |
| Sumitomo Pharma America, Inc. | 16 | $348 |
| Teleflex LLC | 14 | $313 |
| Myriad Genetic Laboratories, Inc. | 16 | $290 |
| Bayer | 15 | $260 |
| Blue Earth Diagnostics | 14 | $239 |
| Tolmar Pharmaceuticals, Inc. | 14 | $215 |
| Urogen Pharma, Inc. | 7 | $130 |
| Vertex | 4 | $106 |
| Urovant Sciences Inc | 7 | $102 |
| Progenics Pharmaceuticals, Inc. | 4 | $90 |
| Accord Healthcare, Inc. | 4 | $77 |
| Ferring Pharmaceuticals Inc. | 3 | $77 |
| AbbVie | 5 | $69 |
| Amgen | 4 | $68 |
| Telix Pharmaceuticals | 4 | $64 |
| Axonics, Inc. | 1 | $54 |
| Novo Nordisk | 3 | $46 |
| Calyxo, Inc. | 2 | $44 |
| Coloplast | 3 | $41 |
| AstraZeneca | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| Sun Pharmaceutical Industries Inc. | 2 | $37 |
| Pharmaand GmbH | 2 | $30 |
| Novocure Inc. | 1 | $23 |
| Procept Biorobotics Corporation | 1 | $20 |
| Novartis | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Olympus America Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Myovant Sciences Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TALZENNA$720
How this compares
$7,212 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 323 | $183,672 |
| GemtesaVibegron | 191 | $116,202 |
| Solifenacin Succinate | 320 | $11,029 |
| Mirabegron ErMirabegron | 16 | $8,119 |
| Tamsulosin Hcl | 465 | $5,283 |
| Silodosin | 13 | $3,891 |
| Methenamine Hippurate | 37 | $2,938 |
| Estradiol | 34 | $2,602 |
| Finasteride | 203 | $2,491 |
| Testosterone | 16 | $2,035 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 30 | $1,885 |
| Trospium Chloride | 41 | $1,768 |
| Oxybutynin Chloride | 83 | $1,388 |
| Cephalexin | 203 | $1,256 |
| NitrofurantoinNitrofurantoin Macrocrystal | 44 | $1,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $569 | $183,672323 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $348 | $116,202191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Wichita
- Constance JacobWichita$65K
- Catherine PowellWichita$50K
- Darine JamaleddineWichita$15K
- Krystal MitchellWichita$13K
- Jolene GrotheWichita$11K
- Christina StantonWichita$11K
- Sarah RookerWichita$10K
- Ayman HamadWichita$9K
- Amanda MogoiWichita$9K
- Jill AugustineWichita$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.